Chinese biotech start-up GenoImmune has secured RMB120 million (US$17.87 million) in a series A round of financing led by GF Xinde Investment Management Co., a private equity affiliate of GF Securities, said GenoImmune in a statement released on Wednesday.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Read 2 Articles for Free with a Basic Account
Gain limited and restricted access to China Money Network.Register Basic Account
Subscribe for an annual subscription!
Enjoy comprehensive and exclusive data you can't find elsewhere!More Info
Already have an account or paid subscription?